RT Journal Article
T1 Impact of Epstein-Barr virus infection on inflammatory bowel disease clinical outcomes
A1 Nunez Ortiz, Andrea
A1 Rojas Feria, Maria
A1 de la Cruz Ramirez, Maria Dolores
A1 Gomez Izquierdo, Lourdes
A1 Trigo Salado, Claudio
A1 Herrera Justiniano, Jose Manuel
A1 Leo Carnerero, Eduardo
K1 Inflammatory bowel disease
K1 Epstein-Barr virus
K1 Lymphoplasmacytosis
K1 lmmunosuppressants
K1 EBER in situ hybridization
K1 Human cytomegalovirus
K1 Colon
K1 Cells
AB Objective: to evaluate the role of Epstein-Barr virus (EBV) on the intestinal mucosa in the evolution of inflammatory bowel disease (IBD). The risk factors for EBV infection and the frequency of EBV-associated lymphoproliferative disorders in IBD patients were also investigated.Methods: intestinal biopsies of IBD patients with available EBV status determined by Epstein-Barr-encoding RNA (EBER) in situ hybridization were identified in the Pathology Database of our center. Clinical information, including phenotypic characteristics of IBD, previous treatments, diagnosis of lymphoma and patient outcome were reviewed in all cases.Results: fifty-six patients with IBD (28 Crohn's disease, 27 ulcerative colitis and one unclassified colitis) were included. EBV in intestinal mucosa was positive in 26 patients (46 %) and was associated to a lymphoproliferative syndrome in one case. EBV positivity was associated with severe histological activity (52 % vs 17.2 %; p 0.007), the presence of a lymphoplasmacytic infiltrate (50 % vs 33.3 %; p 0.03) and active steroid treatment (61.5 % vs 33.3 %; p 0.03). Multi-variate analyses only found an association between EBV and lymphoplasmacytosis (p 0.001). Escalation in previous treatment was significantly more frequent in the EBER+ group (53.8 % vs 26.7 %; p 0.038). No cases developed lymphoma during follow-up.Conclusions: EBV on the intestinal mucosa is associated with a poor outcome of IBD and the need for escalation of therapy. Lymphoplasmacytic infiltrate is associated with EBV infection. EBER+ patients used steroids more frequently compared with EBER- patients. No EBER+ patients developed lymphoma during follow-up.
PB Aran ediciones, s a
SN 1130-0108
YR 2022
FD 2022-01-01
LK http://hdl.handle.net/10668/21702
UL http://hdl.handle.net/10668/21702
LA en
DS RISalud
RD Apr 7, 2025